Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib and TAK-228 in HPV Associated Malignancies
NCT02812056Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of alisertib and sapanisertib in human papillomavirus-associated malignancy, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 21 days. Planned start Sep 2016; status: withdrawn.
02
Drugs
alisertibsapanisertib
03
Conditions
human papillomavirus-associated malignancy
Beyond the preview
Go deeper on NCT02812056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812056.